-

BUYOUT INVESTIGATION ALERT: Kaskela Law Firm Announces Investigation into Fairness of Select Medical Holdings Shareholder Buyout and Encourages Investors to Contact the Firm – SEM

PHILADELPHIA--(BUSINESS WIRE)--Investor protection firm Kaskela Law is investigating Select Medical Holdings Corp. (“Select Medical”) (NYSE: SEM) on behalf of the company’s shareholders to determine whether the recently announced proposed buyout of SEM shareholders is fair and provides investors with sufficient monetary consideration for their shares.

"The investigation has discovered that the transaction appears to have significant conflicts of interest, thus making the sales process and proposed $16.50 per share price unfair to Select Medical shareholders."

Share

Click here for additional information: https://kaskelalaw.com/case/select-medical/

On March 2, 2026, Select Medical announced that it had agreed to be acquired by an investment consortium at a price of $16.50 per share in cash. Upon completion of the proposed transaction, Select Medical’s shareholders will be cashed out of their investment position and the company’s shares will no longer be publicly traded.

Our investigation has discovered that the transaction appears to have significant conflicts of interest, thus making the sales process and proposed $16.50 per share price unfair to Select Medical shareholders. Notably, at the time the buyout was announced, at least one stock analyst was maintaining a price target for Select Medical’s shares of $19.00 per share.

Select Medical shareholders who feel that the buyout price is too low are encouraged to contact Kaskela Law LLC (D. Seamus Kaskela, Esq. or Adrienne Bell, Esq.) at (484) 229 – 0750, or by email at abell@kaskelalaw.com, to receive important information about their time-sensitive legal rights and options. Investors may also request additional information about this matter by clicking on the following link (or by copying and pasting the link into your browser):

https://kaskelalaw.com/case/select-medical/

ABOUT KASKELA LAW:

Kaskela Law exclusively represents investors in securities fraud, corporate governance, and merger & acquisition litigation on a contingent-fee basis. For additional information about the firm, including the firm’s recent monetary recoveries for investors in mergers & acquisition litigation, please visit our website (www.kaskelalaw.com) or contact us today at (888) 715 – 1740.

This communication may constitute attorney advertising in certain jurisdictions.

Contacts

KASKELA LAW LLC
D. Seamus Kaskela, Esquire
Adrienne Bell, Esquire
18 Campus Boulevard, Suite 100
Newtown Square, PA 19073
(484) 229 – 0750
www.kaskelalaw.com

Kaskela Law

NYSE:SEM

Release Versions

Contacts

KASKELA LAW LLC
D. Seamus Kaskela, Esquire
Adrienne Bell, Esquire
18 Campus Boulevard, Suite 100
Newtown Square, PA 19073
(484) 229 – 0750
www.kaskelalaw.com

More News From Kaskela Law

Kaskela Law LLC Announces Investigation of Amneal Pharmaceuticals, Inc. (AMRX) and Encourages AMRX Shareholders to Contact the Firm

PHILADELPHIA--(BUSINESS WIRE)--Kaskela Law is investigating Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal”) on behalf of the company’s current shareholders. The investigation seeks to determine whether Amneal or the company’s officers and/or directors violated the securities laws or breached their fiduciary duties in connection with recent corporate actions. Amneal shareholders are encouraged to contact Kaskela Law LLC (D. Seamus Kaskela, Esq. or Adrienne Bell, Esq.) for additional infor...

Kaskela Law Firm Announces Investigation of DexCom, Inc. (DXCM) and Encourages Long-Term DXCM Shareholders with Investment Losses to Contact the Firm

PHILADELPHIA--(BUSINESS WIRE)--Investor litigation firm Kaskela Law announces that it is investigating DexCom, Inc. (Nasdaq: DXCM) on behalf of the company’s long-term investors. Click here for additional information: https://kaskelalaw.com/case/dexcom-inc/ Recently a securities fraud complaint was filed against DexCom on behalf of investors who purchased shares of the company's stock between January 8, 2024 and September 17, 2025 (the “Wrongdoing Period”). According to the complaint, during th...

Kaskela Law Firm Announces Investigation of Fortrea Holdings Inc. (FTRE) and Encourages Long-Term FTRE Shareholders with Investment Losses to Contact the Firm

PHILADELPHIA--(BUSINESS WIRE)--Investor litigation firm Kaskela Law announces that it is investigating Fortrea Holdings Inc. (Nasdaq: FTRE) (“Fortrea”) on behalf of the company’s long-term investors. Click here for additional information: https://kaskelalaw.com/case/fortrea-holdings/ Recently a securities fraud complaint was filed against Fortrea on behalf of certain investors who purchased shares of the company’s stock between July 5, 2023 and February 28, 2025 (the “Wrongdoing Period”). Accor...
Back to Newsroom